Cell-Assisted Lipotransfer for Cosmetic Breast Augmentation: Supportive Use of Adipose-Derived Stem/Stromal Cells
- First Online:
- Cite this article as:
- Yoshimura, K., Sato, K., Aoi, N. et al. Aesth Plast Surg (2008) 32: 48. doi:10.1007/s00266-007-9019-4
- 6.6k Downloads
Lipoinjection is a promising treatment but has some problems, such as unpredictability and a low rate of graft survival due to partial necrosis.
To overcome the problems with lipoinjection, the authors developed a novel strategy known as cell-assisted lipotransfer (CAL). In CAL, autologous adipose-derived stem (stromal) cells (ASCs) are used in combination with lipoinjection. A stromal vascular fraction (SVF) containing ASCs is freshly isolated from half of the aspirated fat and recombined with the other half. This process converts relatively ASC-poor aspirated fat to ASC-rich fat. This report presents the findings for 40 patients who underwent CAL for cosmetic breast augmentation.
Final breast volume showed augmentation by 100 to 200 ml after a mean fat amount of 270 ml was injected. Postoperative atrophy of injected fat was minimal and did not change substantially after 2 months. Cyst formation or microcalcification was detected in four patients. Almost all the patients were satisfied with the soft and natural-appearing augmentation.
The preliminary results suggest that CAL is effective and safe for soft tissue augmentation and superior to conventional lipoinjection. Additional study is necessary to evaluate the efficacy of this technique further.
KeywordsAdipose-derived stem/stromal cells Breast augmentation Cell therapy Lipoinjection Tissue engineering
Autologous fat transplantation is one promising treatment for facial rejuvenation and soft tissue augmentation because it results in no incisional scar or complications associated with foreign materials. However, certain problems remain, such as unpredictability and a low rate of graft survival due to partial necrosis. Many innovations to overcome these problems have been reported [1, 2, 4, 5, 6, 18] and reviewed previously [4, 14]. On the basis of these reports, we tentatively concluded that we could harvest fat with a 2.5-mm cannula or 18-gauge needle at a vacuum lower than 700 mmHg and reinject it using an 18-gauge needle without significant adipocyte damage .
Lipoinjection can be used to treat facial changes associated with aging and to correct various types of depressed deformities such as hemifacial microsomia and pectus excavatum. It also has been used in breast augmentation by a limited number of plastic surgeons , although the use of autologous fat for breast augmentation has been controversial. Consensus is lacking on whether lipoinjection is safe and appropriate because of microcalcifications that may cause confusion in the evaluation of mammograms. Recently, autologous fat injection has been reevaluated as a potential alternative to artificial implants for breast augmentation [3, 15, 16, 19]. This reevaluation may reflect recent advances in autologous fat transfer and the radiologic detection of breast cancer.
The therapeutic concept of CAL was described in our previous report on preclinical studies . We found that aspirated fat has approximately half the number of ASCs found in excised whole fat. There are two main reasons for this relative deficiency. First, a major portion of the ASCs is located around large vessels and left in the donor site after liposuction . Second, a part of the ASCs is released into the fluid portion of liposuction aspirates . The relative deficiency of ASCs may induce postoperative long-term atrophy of injected fat, as partially confirmed in animal studies [8, 9, 11].
With the CAL strategy, autologous ASCs are used to enhance angiogenesis, to improve the survival rate of grafts, and to reduce postoperative atrophy. In CAL, half the volume of the aspirated fat is processed for isolation of the stromal vascular fraction (SVF) containing ASCs. During the isolation process, the other half of the aspirated fat is prepared for grafting. Freshly isolated SVF, which we characterized previously , is attached to the aspirated fat, with the fat acting as a living scaffold before transplantation. Finally, the SVF-supplemented fat is injected into the target sites. Thus, ASC-poor fat is converted to ASC-rich fat in the preparation process of the injectable material.
In this report, we describe the preliminary results experienced by patients who underwent CAL for cosmetic breast augmentation. This is the first report on the clinical use of ASCs for cosmetic purposes.
Materials and Methods
From 2003 to 2007, we performed CAL for 70 patients: in the breast for 60 patients (including 8 patients who had breast reconstruction after mastectomy), in the face for 12 patients, and in the hip for 1 patient. For three patients, CAL was performed at two sites. Informed consent was obtained from all the patients. The study protocol conformed to the guidelines of the 1975 Declaration of Helsinki and was approved by individual institutional review boards.
No. of cases
40 F, 0 M
35.8 ± 9.1
19.7 ± 1.9
Site of liposuction
Thighs and abdomen
Thighs and lower legs
Total volume of suctioned fat (ml)
1111.8 ± 164.0
Volume of injection (ml)
268.1 ± 47.6
277.3 ± 39.1
Operation time (min)
257.1 ± 39.1
Before the procedure began, the liposuction site was infiltrated with combined saline solution and diluted epinephrine (0.001%). With the patient under general anesthesia, adipose tissue was suctioned using a cannula with a 2.5-mm inner diameter and a conventional liposuction machine. Approximately half of the collected liposuction aspirate was used for isolation of the SVF from both the adipose and fluid portions of the liposuction aspirates, as described previously . This cell processing procedure required about 90 min. During the processing period, the other half of the lipoaspirate was harvested as graft material.
The adipose portion of the liposuction aspirates was either washed several times and placed in an upright position to obtain clear separation of fluids and oil (groups A and B) or centrifuged at 700 g for 3 min without washing (group C), then put into a metal jar (500 ml), which was placed in water with crushed ice. In groups A and C, the fresh SVF isolated from both the adipose and fluid portions was added to the graft material. After gentle mixing and a wait of 10 to 15 min for cell adherence to the aspirated fat, the cell-supplemented fat was put into an injection syringe. In Group B, the freshly isolated SVF was resuspended in 60 ml of saline, then diffusely injected into the whole breast mounds separately (30 ml for each breast) immediately after conventional lipoinjection. There were 6 patients in group A, 2 patients in group B, and 32 patients in group C.
The transplantation of adipose tissue was successfully performed in all cases, and the time of the injection process ranged from 35 to 60 min for both breasts. Subcutaneous bleeding, occasionally seen in some parts of the breasts, resolved in 1 to 2 weeks.
Compared with breast augmentation using implants of the same size, augmentation with CAL showed a lower height but a more natural contour of the breasts. All cases but one (see later) showed natural softness of the breasts without any palpable nodules at 6 months, and all the patients were satisfied with the resulting texture, softness, contour, and absence of foreign materials despite the limited size increase possible with autologous tissue—Cyst formation (<12 mm) was detected by magnetic resonance imaging (MRI) in two patients, and microcalcification was detected by mammogram in two patients at 24 months. In one of two patients in group B, fibrous breast tissue and fibrosis on the sternum were observed by computed tomography (CT) scan at 6 months, and the breasts were found to be harder than in other cases.
Modifications of lipoinjection techniques to improve the survival rate for injected fat have been attempted. From these, it is well accepted that adipose tissue should be placed as small aliquots , preferably within an area 3 mm in diameter . Because it takes a long time to perform ideally diffuse distribution of suctioned fat , we have used a disposable syringe with a threaded plunger and connections, a very long needle (150 mm), and an assistant to rotate the plunger. As a result, only 35 to 60 min are required for injection in both breasts. These devices are critical to performing large-volume lipoinjection safely and precisely in a short time.
In addition, the harvesting, preserving, and refining of graft materials also are important, as repeatedly indicated in the literature. We used a relatively large suction cannula, centrifuged the aspirated fat in some cases, and kept it cooled until transplantation. In this study, the clinical results (increase in breast circumference) appeared to be better in group C (using centrifuged fat) than in group A (using noncentrifuged fat), although quantitative measurement and statistical comparison were not done. In a previous study, we found that centrifugation of aspirated fat is substantially influential because centrifugation at 1,200 g decreases the fat volume by 30%, damaging 12% of the adipocytes and 0% of the ASCs. This leads to the concentration of cell numbers per volume of adipocytes and ASCs by 25% and 43%, respectively .
In addition, centrifugation may be especially beneficial in our treatment because water content in the graft material may disturb the adherence of ASCs to the adipose tissue and interfere with differentiation into expected lineages. Any ASCs floating in a solution, which is a nonphysiologic environment, may migrate over distances, penetrate into the lymphatic flow, and differentiate unexpectedly. We believe that such migration and altered cell differentiation caused the development of fibrotic tissue on the sternum of one patient in group B. Thus, we conclude that centrifuged fat combined with ASCs as cell pellets (group C procedure) was best among the three methods used in this study.
Although small cystic formation and microcalcification were detected in some cases, the microcalcification was easily distinguished from that associated with breast cancer, and the overall cosmetic results were generally satisfactory and encouraging. Almost all the patients were satisfied with their enlarged and soft breasts with a natural contour. Both CT scans and MRI showed that transplanted fat tissue survived and formed a significant thickness of the fatty layer not only subcutaneously on and around the mammary glands, but also between the mammary glands and the pectoralis muscles. Breast volume stabilized 2 to 3 months after transplantation.
Maximum breast augmentation using the described technique varied among the patients and appeared to be 100 to 200 ml. Although these volumes may be smaller than those achieved with large artificial implants, a definite advantage is that patients need not be concerned about postoperative complications induced by artificial implants such as rupture, infection, capsular contracture, unnatural contour, hardness, neurologic symptoms, and immune response. Compared with our dozens of patients who underwent conventional autologous lipoinjection to the breasts, augmentation effects were apparently higher with CAL. A 2- to 3-cm increase in breast circumference was common with the conventional procedure, compared with the 4- to 8-cm increase seen in this trial of CAL, although the augmentation effect varied among patients. The measurement system we recently devised may help to quantify the difference in augmented volume in the future.
Adipose tissue contains not only adipogenic progenitor cells, but also multipotent stem cells, which can differentiate into fat, bone, cartilage, and types of tissue [21, 22]. Suctioned fat appears to lose a significant number of these precursors during liposuction and the preparation processes as compared with nonsuctioned adipose tissue . This relative deficiency of precursors may contribute to the low survival rate and long-term atrophy of transplanted lipoaspirates. In CAL, the deficit of ASCs was compensated by supplementing ASCs. To maximize the biologic function and avoid unexpected behavior of ASCs, it seems important to ensure adherence of supplemented ASCs to adipocytes or connective tissue.
With this novel treatment, ASCs have four possible roles, which were partly confirmed in preclinical studies [8, 9, 11]. First, ASCs can differentiate into adipocytes and contribute to the regeneration of adipose tissue. Second, ASCs can differentiate into endothelial cells and also probably into vascular mural cells [8, 10, 12], resulting in the promotion of angiogenesis and graft survival. Third, ASCs are known to release angiogenic growth factors in response to hypoxia and other conditions , and these factors influence surrounding host tissue. In their final role, which may be the most influential, ASCs survive as original ASCs . In the adipose tissue, ASCs reside between adipocytes or in the extracellular matrix, especially around vessels, and contribute to the turnover of adipose tissue, which is known to be very slow (2 years or more) . However, adipose grafts probably turn over during the first 2 to 3 months after transplantation because they experience temporary ischemia followed by reperfusion injury. This turnover, the replacement process of the adipose tissue, is conducted by tissue-specific progenitor cells, which are ASCs. The relative deficiency of ASCs in aspirated fat may affect the replacement process and lead to postoperative atrophy of grafted fat, which is known to occur commonly during the first 6 months after lipoinjection.
The freshly isolated SVF used in CAL contains not only ASCs but also vascular endothelial cells, pericytes, blood cells (both white and red), and other cells, as previously described . After transplantation, ASCs may interact with other cells such as vascular endothelial cells, and supplementation with the SVF may be superior to supplementation with ASCs alone in this treatment. However, further studies are needed to elucidate the synergistic effects of ASCs with other cells contained in the graft.
In this preliminary study, satisfactory clinical results were generally achieved without any major complications. Thus, we can conclude that CAL is sufficiently safe for continuation of the study, though controlled investigations and accumulated long-term results are needed to elucidate the overall safety and efficacy of the treatment. A variety of new innovations, including stem cell technology, may be developed and may contribute to the improvement of autologous tissue transplantation and regeneration. Further improvements of the technique may cause autologous tissue transfer to become the first choice for breast augmentation in the future.